For which adults with triple-negative breast cancer is Trodelvy (sacituzumab govitecan) indicated?

Trodelvy (sacituzumab govitecan) is indicated for adults with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least two prior lines of systemic therapy, including at least one for unresectable locally advanced or metastatic disease.